JPMorgan Chase & Co’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.02M | Sell |
399,503
-418,821
| -51% | -$2.12M | ﹤0.01% | 3337 |
|
|
2025
Q1 | $4.33M | Sell |
818,324
-238,843
| -23% | -$1.26M | ﹤0.01% | 2764 |
|
|
2024
Q4 | $7.15M | Sell |
1,057,167
-119,024
| -10% | -$805K | ﹤0.01% | 2500 |
|
|
2024
Q3 | $7.75M | Buy |
1,176,191
+67,464
| +6% | +$445K | ﹤0.01% | 2337 |
|
|
2024
Q2 | $8.32M | Buy |
1,108,727
+26,622
| +2% | +$200K | ﹤0.01% | 2219 |
|
|
2024
Q1 | $10.8M | Buy |
1,082,105
+701,295
| +184% | +$6.99M | ﹤0.01% | 2068 |
|
|
2023
Q4 | $3.75M | Sell |
380,810
-574,089
| -60% | -$5.66M | ﹤0.01% | 2740 |
|
|
2023
Q3 | $7.3M | Buy |
954,899
+580,038
| +155% | +$4.44M | ﹤0.01% | 2194 |
|
|
2023
Q2 | $2.8M | Buy |
374,861
+65,347
| +21% | +$488K | ﹤0.01% | 2841 |
|
|
2023
Q1 | $2.06M | Buy |
309,514
+136,178
| +79% | +$908K | ﹤0.01% | 3019 |
|
|
2022
Q4 | $1.34M | Sell |
173,336
-7,802
| -4% | -$60.2K | ﹤0.01% | 3210 |
|
|
2022
Q3 | $1.93M | Buy |
181,138
+11,788
| +7% | +$125K | ﹤0.01% | 2942 |
|
|
2022
Q2 | $1.38M | Buy |
169,350
+42,311
| +33% | +$345K | ﹤0.01% | 3267 |
|
|
2022
Q1 | $910K | Sell |
127,039
-29,390
| -19% | -$211K | ﹤0.01% | 3681 |
|
|
2021
Q4 | $2.68M | Buy |
156,429
+124,826
| +395% | +$2.14M | ﹤0.01% | 3026 |
|
|
2021
Q3 | $727K | Buy |
31,603
+11,611
| +58% | +$267K | ﹤0.01% | 3778 |
|
|
2021
Q2 | $730K | Buy |
+19,992
| New | +$730K | ﹤0.01% | 3805 |
|